Advertisement
Screener

Eledon Pharmaceuticals, Inc. (ELDN) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

1.4 / 5 stars · 15/54 Roast Me

Eledon Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

Eledon Pharmaceuticals, Inc. (ELDN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $16.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets

us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19

  • Eledon Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $16.60M, a 6.41% increase from fiscal 2024.
  • Eledon Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $15.60M, a 71.43% increase from fiscal 2023.
  • Eledon Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $9.10M, a 0.00% change from fiscal 2022.
  • Eledon Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $9.10M, a 3.19% decline from fiscal 2021.
Period endValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 monthValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed
2025-12-31$16.60M
10-K · filed 2026-03-19
2024-12-31$15.60M
10-K · filed 2026-03-19
2023-12-31$9.10M
10-K/A · filed 2025-08-14
2022-12-31$9.10M
10-K/A · filed 2024-08-19
$9.40M
10-K · filed 2023-03-30
2021-12-31$9.40M
10-K/A · filed 2024-08-19
$6.40M
10-K · filed 2022-03-24
2020-12-31$6.40M
10-K · filed 2023-03-30
-$5.10M
10-K · filed 2021-03-31
2019-12-31-$5.10M
10-K · filed 2022-03-24
$3.00M
10-K · filed 2020-03-17
2018-12-31$3.00M
10-K · filed 2019-03-28
2017-12-31$1.70M
10-K · filed 2018-04-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Nkarta, Inc. (NKTX)United States$0.205B-1.73
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12